The claims of the patent cover methods of using biOasis’ brain penetrating drug delivery vector, Transcend, coupled with a lysosomal storage disease enzyme for the treatment of lysosomal storage diseases (LSD).
Specifically, the Transcend-coupled enzymes claimed in the patent allowance include those that are used clinically as enzyme replacement therapies to treat lysosomal storage diseases, such as Hunter Syndrome, Hurler syndrome and others.
biOasis Technologies CEO Rob Hutchison noted that these patent allowances in Canada and Europe complement the company’s existing issued LSD-related US patent and mark another major step towards international exclusivity in the rare disease market.
"We believe it helps validates our Transcend vector technology for treating LSD and particularly its special ability to deliver therapeutic compounds across the blood-brain barrier," Hutchison added.
biOasis’ corresponding LSD therapeutic patent issued in the US on 1 October 2013 as US 8,546,319.
A patent allowance represents the official communications from the responsible patent authorities that an application will be issued upon final review and payment of the issuance fee.